Market Newsdesk

Genprex, Inc. Announces Closing Of $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Without Warrants

Proceeds will add resources for the Company’s Acclaim-1 and Acclaim-2 clinical trials in lung cancer, as well as its pre-clinical programs in cancer and diabetes

AUSTIN, Texas–(BUSINESS WIRE)–
Genprex, Inc. (Nasdaq: GNPX) (“Genprex” or the “Company”), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the closing of its previously announced registered direct offering of 3,116,884 shares of its common stock with a single healthcare-dedicated institutional investor. The offering was priced at-the-market under Nasdaq rules at a price of $3.85 per share for gross proceeds to the Company of $12 million, before deducting commissions and estimated offering expenses. There were no warrants issued in the offering.

“We believe that the closing of this transaction with a single, healthcare dedicated institutional investor is further evidence that the potential of our gene therapies for cancer and diabetes is gaining recognition within the community of sophisticated healthcare investors. The proceeds will provide additional resources to conduct our Acclaim-1 and Acclaim-2 clinical trials, combining our gene therapy, REQORSA, with Tagrisso (by Astra Zeneca) and Keytruda (by Merck & Co.), respectively, for the treatment of non-small cell lung cancer, as well as continue the pursuit of our pre-clinical programs in cancer and diabetes, and to potentially acquire additional technologies for our pipeline,” said Rodney Varner, President and Chief Executive Officer of Genprex.

A.G.P./Alliance Global Partners acted as sole placement agent for the offering.

The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes.

The securities were offered pursuant to an effective shelf registration statement on Form S-3 (File No. 333-239134) previously filed with the U.S. Securities and Exchange Commission (the “SEC”).

A prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available for free on the SEC’s website at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Genprex

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company’s lead product candidate, REQORSA™ (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso®) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone.

For more information, please visit the Company’s web site at www.genprex.com or follow Genprex on Twitter, Facebook and LinkedIn.

Forward Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and Private Securities Litigation Reform Act, as amended, including those relating to the intended use of proceeds of the offering and other statements that are predictive in nature. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events and involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any results, performance or achievements expressed or implied by the forward-looking statements. Such factors include the risk factors set forth in the Company’s filings with the SEC, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2019, its Quarterly Reports on Form 10-Q and its Current Reports on Form 8-K filed in 2020, as well as the risks identified in the shelf registration statement and the prospectus supplement relating to the offering. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. Genprex undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201224005195/en/

Genprex, Inc.

(877) 774-GNPX (4679)

Investor Relations

GNPX Investor Relations

(877) 774-GNPX (4679) Ext. #2

[email protected]

Media Contact

Genprex Media Relations

Kalyn Dabbs

(877) 774-GNPX (4679) Ext. #3

[email protected]

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: Oncology Health Diabetes Genetics Clinical Trials Biotechnology

MEDIA:

Logo

INVESTOR ALERT: Kirby McInerney LLP Reminds Investors That a Class Action Has Been Filed Against GoodRx Holdings, Inc. and Encourages Investors to Contact the Firm Before February 16, 2021

NEW YORK–(BUSINESS WIRE)–
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Central District of California on behalf of those who acquired GoodRx Holdings, Inc. (“GoodRx” or the “Company”) (NASDAQ: GDRX) securities during the period from September 23, 2020 through November 16, 2020 (the “Class Period”). Investors have until February 16, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

The lawsuit alleges that at the time of the initial public stock offering (the “IPO”), the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Specifically, the complaint alleges that on September 23, 2020, GoodRX completed its IPO. The lawsuit alleges that Defendants timed the IPO before Amazon announced its online pharmaceutical business, making their statements in the Registration Statement and during the Class Period about GoodRx’s competitive position materially false and/or misleading. The lawsuit also alleges that due to these materially false and/or misleading statements, GoodRx Class A common stock traded at artificially inflated prices of more than $64 per share during the Class Period.

Then, just weeks later on November 17, 2020, Amazon announced its Prime Rx plan and a discount card program, which was said to make it “simple for customers to compare prices and purchase medications for home delivery, all in one place.” Following this news, GoodRx Class A common stock dropped approximately 23%, from $46.72 per share to $36.21 by close on November 17, 2020.

If you acquired GoodRx securities, have information, or would like to learn more about these claims, please contact Thomas W. Elrod of Kirby McInerney at 212-371-6600, by email at [email protected], or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, and whistleblower litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney’s website: www.kmllp.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201224005201/en/

Kirby McInerney LLP

Thomas W. Elrod, Esq., (212) 371-6600

[email protected]

www.kmllp.com

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo

Warrior Gold Announces Closing of Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

TORONTO–(BUSINESS WIRE)–Warrior Gold Inc. (TSX-V – WAR) (“Warrior Gold” or the “Company”) is pleased to announce that further to its press releases of December 1 and 18^th, the Company has closed the previously announced private placement financing with the issuance of 11,262,812 units raising an aggregate of $1,176,633 in gross proceeds. The 11,262,812 units were issued as to 6,347,811 common share units (the “HD Units”), 1,809,000 flow-through share units (the “FT Units”) and 3,106,001 charity flow-through share units (the “Charity FT Units”) priced at $0.09 per HD Unit, $0.12 per FT Unit and $0.125 per Charity FT Unit (the “Private Placement”). Each Unit comprises one common share, and in the case of the FT and Charity FT Units, one flow-through share, and one-half of one common share purchase warrant (each whole common share purchase warrant, a “Warrant”) with each Warrant entitling the holder to purchase one additional common share in the capital of the Company for a period of 18 months from the date of closing of the Private Placement, at a purchase price of $0.15 per common share, provided, however, that, if, at any time following the statutory four-month hold period, the closing price of the common shares on the TSX Venture Exchange is greater than $0.20 for 20 or more consecutive trading days, the Warrants will be accelerated and will expire on the 30^th business day following the date of such notice. All securities issued under the Private Placement will be subject to a four-month and one day “hold period” under applicable Canadian securities legislation.

Certain insiders of the Company subscribed for an aggregate of $48,000 in FT Units pursuant to the Private Placement.

In accordance with the policies of the TSX Venture Exchange, the Company paid $41,679 in cash and issued 458,228 compensation warrants exercisable into common shares of the Company at $0.15 for a period of 18 months from the closing of the Private Placement.

The gross proceeds from the sale of the HD Units will be utilized by the Company for working capital and general corporate purposes and the gross proceeds from the sale of the FT and Charity Units will be used by the Company to incur eligible “Canadian exploration expenses” that will qualify as “flow-through mining expenditures” as such terms are defined in the Income Tax Act (Canada) (the “Qualifying Expenditures”) related to the Company’s Goodfish-Kirana Property located in Kirkland Lake, Ontario.

The securities offered have not been registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.

About Warrior Gold Inc.

Warrior Gold is a TSX Venture Exchange listed company that owns the Goodfish-Kirana Property located five km from the town of Kirkland Lake, Ontario. The Property is located in the historic Kirkland Lake Gold Camp which is situated in the prolific Abitibi Greenstone Belt, recognized as one of the world’s highest grade greenstone belts with over 200 million ounces of gold produced to date.

The Goodfish-Kirana Property is 11.5 km long by roughly three km wide (34 km²) and contains three major structural trends: the east-west trending Kirana Deformation Zone; the northeast-trending Goodfish Deformation Zone; and the Victoria Creek Deformation Zone on the recently acquired Sutton claims on the northeast side of the property. The Property contains numerous historical gold showings, as well as 18 historical pits and shafts.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements: This press release contains forward-looking statements. Forward-looking statements are frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “would”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. The forward-looking statements are based on certain key expectations and assumptions made by the Company. Although Warrior Gold believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because Warrior Gold can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. In addition to other risks that may affect the forward-looking statements in this press release are those set out in the Company’s management discussion and analysis of the financial condition and results of operations for the year ended March 31, 2020 and the second quarter ended September 30, 2020, which are available on the Company’s profile at www.sedar.com. The forward-looking statements contained in this press release are made as of the date hereof and Warrior Gold undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201224005199/en/

Danièle Spethmann, P.Geo.

President & CEO

+1 647 344-3433

[email protected]

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Mining/Minerals Natural Resources

MEDIA:

Posted on December 24, 2020 12:03 pm

HPQ JAN 4 DEADLINE: Zhang Investor Law Alerts Investors to Deadline in Securities Class Action Lawsuit Against  HP Inc. – HPQ

NEW YORK, Dec. 24, 2020 (GLOBE NEWSWIRE) — Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of HP Inc. (NYSE: HPQ)  between November 6, 2015 and June 21, 2016, inclusive (the “Class Period”).

To join the class action, go to http://zhanginvestorlaw.com/join-action-form/?slug=hp-inc-2&id=2482 or call Sophie Zhang, Esq. toll-free at 800-991-3756 or email [email protected] for information on the class action.

如果您想加入这个集体诉讼案，请在这里提交您的信息。http://zhanginvestorlaw.com/join-action-form/?slug=hp-inc-2&id=2482

If you wish to serve as lead plaintiff, you must move the Court before January 4, 2021 DEADLINE.   A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. 

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose, among other things: HP’s channel inventory management and sales practices resulted in the sale of supplies to customers that did not need or want the product in order to artificially increase revenues and profits; HP’s channel inventory management and sales practices resulted in the sale of supplies to customers outside of designated regions at unsustainable discounts in order to artificially increase revenues and profits; HP’s channel inventory management and sales practices resulted in the sale of supplies at steep discounts to customers to encourage those customers to sell the supplies further down the supply channel, out of HP’s inventory management metrics; and as a result, defendants’ statements about HP’s business condition and prospects were materially false and misleading when made. When the true details entered the market, the lawsuit claims that investors suffered damages.

Zhang Investor Law represents investors worldwide. Attorney Advertising. Prior results do not guarantee similar outcomes.

Zhang Investor Law P.C.
99 Wall Street, Suite 232
New York, New York 10005
[email protected]
tel: (800) 991-3756

Posted on December 24, 2020 12:03 pm

INVESTOR ALERT: Kirby McInerney McInerney Reminds Investors That a Class Action Lawsuit Has Been Filed Against Qiwi plc and Encourages Investors to Contact the Firm Before February 9, 2021

NEW YORK, Dec. 24, 2020 (GLOBE NEWSWIRE) — The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Eastern District of New York on behalf of those who acquired Qiwi plc (“Qiwi” or the “Company”) (NASDAQ: QIWI) securities during the period from March 28, 2019 through December 9, 2020, inclusive (the “Class Period”). Investors have until February 9, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Qiwi’s internal controls related to reporting and record-keeping were ineffective; (2) consequently, the Central Bank of Russia would impose a monetary fine upon the Company and impose restrictions upon the Company’s ability to make payments to foreign merchants and transfer money to pre-paid cards; and (3) as a result, Defendants’ public statements were materially false and/or misleading at all relevant times.

On December 9, 2020, after the market closed, Qiwi filed a Form 6-K with the SEC, announcing that the Central Bank of Russia had imposed a fine of approximately $150,000 for deficient record-keeping and reporting, and suspended the Company’s conduct most types of payments to foreign merchants and money transfers to pre-paid cards from corporate accounts. On this news, Qiwi’s ADS price fell $2.80 per share, or 20.6%, to close at $10.79 per share on December 10, 2020.

If you acquired Qiwi securities, have information, or would like to learn more about these claims, please contact Thomas W. Elrod of Kirby McInerney at 212-371-6600, by email at [email protected], or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, and whistleblower litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney’s website: www.kmllp.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq., (212) 371-6600
[email protected]
www.kmllp.com